Sana Biotechnology
SANA
2.70
-0.02
-0.74%
Sana Biotechnology
US · SANA
#3404 by market cap
Listed 2021
2.70
-0.02
-0.74%
Live - 5344 symbols - heartbeat 357s ago
· 2026-10-08 09:59
Pre-market
2.72
0.00%
After-hours
2.80
+2.94%
Overnight
2.77
+1.84%
- Market cap
- 808.27M
- P/E (TTM)i
- -3.60
- P/Bi
- 5.23
- EPSi
- -0.96
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on SANA?
Anonymous reader poll. Unscientific, not investment advice.
Recent news
-
Rating change
Citi Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $12Market Newswire · 2026/3/5
-
Rating change
TD Cowen Maintains Sana Biotechnology(SANA.US) With Buy RatingMarket Newswire · 2026/8/12
-
H.C. Wainwright Remains a Buy on Sana Biotechnology (SANA)TipRanks · 2026/9/22
-
Rating change
Rodman & Renshaw Initiates Sana Biotechnology(SANA.US) With Buy Rating, Announces Target Price $16Market Newswire · 2026/5/11
-
Wedbush Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $7Market Newswire · 2026/8/11
-
Rating change
BofA Securities Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $7Market Newswire · 2026/5/13
-
Company notice
Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Officer Wyrick Susan D.SEC · 2026/3/5
-
Company notice
4: Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Bilenker Joshua H.SEC · 2026/6/6
-
H.C. Wainwright Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $7Market Newswire · 2026/9/22
-
Rating change
Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE), AgomAb Therapeutics NV ADR (AGMB) and Sana Biotechnology (SANA)TipRanks · 2026/8/17
-
Rating change
A Quick Look at Today's Ratings for Sana Biotechnology(SANA.US), With a Forecast Between $7 to $16Market Newswire · 2026/5/12
-
Rating change
TD Cowen Maintains Sana Biotechnology(SANA.US) With Buy Rating, Announces Target Price $3.21Market Newswire · 2026/4/14
-
Rating change
Wedbush Maintains Sana Biotechnology(SANA.US) With Buy Rating, Raises Target Price to $7Market Newswire · 2026/4/14
-
BofA Securities Maintains Sana Biotechnology(SANA.US) With Buy Rating, Cuts Target Price to $6Market Newswire · 2026/8/14
-
Rating change
Morgan Stanley Maintains Sana Biotechnology(SANA.US) With Buy Rating, Cuts Target Price to $3.07Market Newswire · 2026/5/18
-
Morgan Stanley Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $12Market Newswire · 2026/8/17
-
Company notice
Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Officer Wyrick Susan D.SEC · 2026/3/11
-
Company notice
Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Rosiello Robert L.SEC · 2026/6/6
-
Company notice
Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Officer Wyrick Susan D.SEC · 2026/3/7
-
Rating change
Analysts Offer Insights on Healthcare Companies: Sana Biotechnology (SANA) and Rapport Therapeutics, Inc. (RAPP)TipRanks · 2026/3/11
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-10-08 09:59:55 · For reference only, not investment advice and not tailored to your situation.